Sunovion gains Elevation in respiratory sector with promising nebulised COPD contender
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma's Sunovion Pharmaceuticals unit will pay $100 million upfront and up to $330 million in milestone payments to acquire Elevation Pharmaceuticals, based on positive Phase IIb data in moderate to severe chronic obstructive pulmonary disease (COPD) for the private San Diego-based company's nebulised long-acting muscarinic antagonist (LAMA) EP-101.